Shattuck Labs, Inc. (STTK)
NASDAQ: STTK · Real-Time Price · USD
6.26
-0.41 (-6.15%)
At close: May 15, 2026, 4:00 PM EDT
6.00
-0.26 (-4.15%)
After-hours: May 15, 2026, 5:19 PM EDT
Shattuck Labs Revenue
In the year 2025, Shattuck Labs had annual revenue of $1.00M, down -82.52%.
Revenue (ttm)
$1.00M
Revenue Growth
-82.52%
P/S Ratio
504.13
Revenue / Employee
$25,000
Employees
40
Market Cap
473.14M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.00M | -4.72M | -82.52% |
| Dec 31, 2024 | 5.72M | 4.06M | 245.26% |
| Dec 31, 2023 | 1.66M | 1.01M | 154.14% |
| Dec 31, 2022 | 652.00K | -29.37M | -97.83% |
| Dec 31, 2021 | 30.02M | 20.08M | 202.16% |
| Dec 31, 2020 | 9.93M | 47.00K | 0.48% |
| Dec 31, 2019 | 9.89M | -12.56M | -55.94% |
| Dec 31, 2018 | 22.44M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| 4D Molecular Therapeutics | 88.24M |
| Fulcrum Therapeutics | 80.00M |
| Assembly Biosciences | 71.10M |
| Prothena Corporation | 57.94M |
| XOMA Royalty | 48.56M |
| Ovid Therapeutics | 7.12M |
| Ocugen | 4.47M |
| Neurogene | 925.00K |
STTK News
- 7 days ago - Shattuck Labs price target raised to $11 from $8 at Wedbush - TheFly
- 8 days ago - Shattuck Labs reports Q1 EPS (13c), consensus (13c) - TheFly
- 8 days ago - Shattuck Labs sees cash and cash equivalents sufficient into 2029 - TheFly
- 8 days ago - Shattuck Labs Reports First Quarter 2026 Financial Results and Recent Business Highlights - GlobeNewsWire
- 18 days ago - Shattuck Labs initiated with an Overweight at Cantor Fitzgerald - TheFly
- 25 days ago - Shattuck Labs price target raised to $18 from $6 at H.C. Wainwright - TheFly
- 6 weeks ago - Shattuck Labs management to meet with Piper Sandler - TheFly
- 2 months ago - Citi ups Shattuck Labs target, opens ‘upside 90-day catalyst watch’ - TheFly